Krystal Biotech Q2 revenue rises on VYJUVEK strength
KRYS•Outlook
- Krystal Biotech expects VYJUVEK launches in Spain and Italy before year end
- Company expects multiple clinical data readouts in 2H 2026
- Company sees FY 2026 non-GAAP R&D and SG&A expense at $175 mln to $195 mln
Result drivers
- VYJUVEK demand - Co said Q2 revenue growth was driven by durable demand for VYJUVEK in the US and internationally, with expanding prescriber base and broad reimbursement access
- Patient support initiatives - Co said patient support programs and a recent label update helped DEB patients integrate VYJUVEK into ongoing wound care routines
Analyst coverage
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the pharmaceuticals peer group is "buy"
- Wall Street's median 12-month price target for Krystal Biotech Inc is $386.50, about 13.3% above its July 31 closing price of $341.12
- The stock recently traded at 40 times the next 12-month earnings vs. a P/E of 31 three months ago
